Advances in IL-7 Research on Tumour Therapy

Pharmaceuticals (Basel). 2024 Mar 25;17(4):415. doi: 10.3390/ph17040415.

Abstract

Interleukin-7 (IL-7) is a versatile cytokine that plays a crucial role in regulating the immune system's homeostasis. It is involved in the development, proliferation, and differentiation of B and T cells, as well as being essential for the differentiation and survival of naïve T cells and the production and maintenance of memory T cells. Given its potent biological functions, IL-7 is considered to have the potential to be widely used in the field of anti-tumour immunotherapy. Notably, IL-7 can improve the tumour microenvironment by promoting the development of Th17 cells, which can in turn promote the recruitment of effector T cells and NK cells. In addition, IL-7 can also down-regulate the expression of tumour growth factor-β and inhibit immunosuppression to promote anti-tumour efficacy, suggesting potential clinical applications for anti-tumour immunotherapy. This review aims to discuss the origin of IL-7 and its receptor IL-7R, its anti-tumour mechanism, and the recent advances in the application of IL-7 in tumour therapy.

Keywords: IL-7; anti-tumour mechanisms; tumour therapy.

Publication types

  • Review

Grants and funding

This research was funded by the National Natural Science Foundation of China (grant number 31140018) and Tianchi Talent Introduction Plan Innovative Leader.